Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAPTER-Platform-201: pimitespib with or without enzalutamide in metastatic castration-resistant prostate cancer
jRCT2031230263Phase 2Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pimitespib and enzalutamide in prostate cancer (PCa) (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity and Radiographic progression-free survival. Started Aug 2023; status: active, not recruiting.
02
Drugs
pimitespibenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031230263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230263.